7 News & Press Releases found
Bexson Biomedical News
-
Bexson Biomedical Granted USPTO Patent Allowance on Proprietary Formulation Technology, SeValent
Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the small molecule injectable market and enabling home health solutions, today announced the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for ...
-
Bexson Biomedical Announces Participation in the Jeffries Innovation in Mental Health Summit
Bexson Biomedical, Inc., a biopharmaceutical company focused on disrupting the $189 billion small molecule injectable market and enabling home health solutions, today announced that the Company’s management will be participating in the 2022 ...
-
Stevanato Group S.p.A. and Bexson Biomedical, Inc. Expand Collaboration to Treat a Range of Mental Health Conditions With an On-body Device
Italian-based Stevanato Group S.p.A., a global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, and Bexson Biomedical, Inc., a research stage company developing ...
-
Bexson Biomedical Granted USPTO Patent On Proprietary Ketamine Formulation
Bexson Biomedical, Inc., a research-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. Patent and Trademark Office (USPTO) has granted Bexson U.S. ...
-
Bexson Biomedical Hires Veteran Medical Device Development Leader, Will Focus On New Dosing & Delivery Solutions For Controlled Substances
Bexson Biomedical, Inc., a research-stage company developing dosing and delivery solutions for mental health and pain management indications, announced today the addition of medical device and combination product developer, Sheldon Moberg, to its ...
-
Bexson Biomedical Raises $4.8 Million In Oversubscribed Series A
Bexson Biomedical, Inc., a research-stage company developing a subcutaneous ketamine treatment platform for pain management and mental health disorders, announced today that they closed a $4.8 million Series A round of financing. Funding will ...
-
Bexson Biomedical To Co-Host Virtual Ketamine Conference
Bexson Biomedical, Inc. will be co-hosting "The Ketamine Conference – A Molecular Masterclass" on August 21-22. The two-day virtual conference will include 12 different panel sessions focused on the latest science, clinical innovations, and ...